Wuhan QR Pharmaceuticals

Wuhan QR Pharmaceuticals is a clinical-stage biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's research and development efforts are primarily focused on oncology and cardiovascular diseases, aiming to address significant unmet medical needs. Its lead clinical candidate, QR-101, is a potent and selective PARP inhibitor currently undergoing Phase 2 clinical trials for the treatment of various solid tumors, including ovarian cancer. Additionally, the company is advancing QR-001, a P2Y12 receptor antagonist designed for the management of thrombotic disorders. Wuhan QR Pharmaceuticals leverages its location in the Wuhan National Bio-industry Park to foster growth and collaborate within the regional biotechnology ecosystem.